Ambient

Butyraldehyde

Butyraldehyde

Butyraldehyde

Butyraldehyde

Butyric Acid

Butyric Acid

Butyrophenone

Butyrophenone

Butyrophenone

Butyryl Chloride

Butyryl Chloride

This Antibody recognizes c-Myc tagged fusion proteins.

This Antibody recognizes c-Myc tagged fusion proteins.

CA125, known as cancer antigen 125, carcinoma antigen 125, and carbohydrate antigen 125, is a member of the mucin family glycoproteins. It is involved in boosting tumorigenesis and tumor proliferation and is considered as a useful biomarker for the diagnosis of ovarian cancer.

CA125, known as cancer antigen 125, carcinoma antigen 125, and carbohydrate antigen 125, is a member of the mucin family glycoproteins. It is involved in boosting tumorigenesis and tumor proliferation and is considered as a useful biomarker for the diagnosis of ovarian cancer.

CA125, known as cancer antigen 125, carcinoma antigen 125, and carbohydrate antigen 125, is a member of the mucin family glycoproteins. It is involved in boosting tumorigenesis and tumor proliferation and is considered as a useful biomarker for the diagnosis of ovarian cancer.

CA125, known as cancer antigen 125, carcinoma antigen 125, and carbohydrate antigen 125, is a member of the mucin family glycoproteins. It is involved in boosting tumorigenesis and tumor proliferation and is considered as a useful biomarker for the diagnosis of ovarian cancer.

CA125, known as cancer antigen 125, carcinoma antigen 125, and carbohydrate antigen 125, is a member of the mucin family glycoproteins. It is involved in boosting tumorigenesis and tumor proliferation and is considered as a useful biomarker for the diagnosis of ovarian cancer.

CA125, known as cancer antigen 125, carcinoma antigen 125, and carbohydrate antigen 125, is a member of the mucin family glycoproteins. It is involved in boosting tumorigenesis and tumor proliferation and is considered as a useful biomarker for the diagnosis of ovarian cancer.

MUC16, also known as the CA125 antigen, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.

CA15-3
(Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a
membrane-anchored, mucin-type glycoprotein present in malignant cells. It is
used as tumor marker to monitor breast cancer treatment and disease recurrence.

CA15-3
(Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a
membrane-anchored, mucin-type glycoprotein present in malignant cells. It is
used as tumor marker to monitor breast cancer treatment and disease recurrence.

CA15-3
(Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a
membrane-anchored, mucin-type glycoprotein present in malignant cells. It is
used as tumor marker to monitor breast cancer treatment and disease recurrence.

CA15-3
(Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a
membrane-anchored, mucin-type glycoprotein present in malignant cells. It is
used as tumor marker to monitor breast cancer treatment and disease recurrence.

CA15-3
(Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a
membrane-anchored, mucin-type glycoprotein present in malignant cells. It is
used as tumor marker to monitor breast cancer treatment and disease recurrence.

CA15-3
(Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a
membrane-anchored, mucin-type glycoprotein present in malignant cells. It is
used as tumor marker to monitor breast cancer treatment and disease recurrence.

CA15-3 (Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a membrane-anchored, mucin-type glycoprotein present in malignant cells. It is used as tumor marker to monitor breast cancer treatment and disease recurrence.

CA15-3 (Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a membrane-anchored, mucin-type glycoprotein present in malignant cells. It is used as tumor marker to monitor breast cancer treatment and disease recurrence.

CA15-3 (Carcinoma antigen 15-3) is also known as MUC 1 antigen. It is a membrane-anchored, mucin-type glycoprotein present in malignant cells. It is used as tumor marker to monitor breast cancer treatment and disease recurrence.

Carbohydrate
antigen 19-9 (CA19-9) is the sialylated form of Lewis Antigen. It may be
elevated in many types of gastrointestinal cancer, such as colorectal cancer,
esophageal cancer and hepatocellular carcinoma. It is useful for diagnosis and monitoring of
pancreatic cancer

Carbohydrate
antigen 19-9 (CA19-9) is the sialylated form of Lewis Antigen. It may be
elevated in many types of gastrointestinal cancer, such as colorectal cancer,
esophageal cancer and hepatocellular carcinoma. It is useful for diagnosis and monitoring of
pancreatic cancer

Carbohydrate
antigen 19-9 (CA19-9) is the sialylated form of Lewis Antigen. It may be
elevated in many types of gastrointestinal cancer, such as colorectal cancer,
esophageal cancer and hepatocellular carcinoma. It is useful for diagnosis and monitoring of
pancreatic cancer

Carbohydrate
antigen 19-9 (CA19-9) is the sialylated form of Lewis Antigen. It may be
elevated in many types of gastrointestinal cancer, such as colorectal cancer,
esophageal cancer and hepatocellular carcinoma. It is useful for diagnosis and monitoring of pancreatic cancer

Carbohydrate
antigen 19-9 (CA19-9) is the sialylated form of Lewis Antigen. It may be
elevated in many types of gastrointestinal cancer, such as colorectal cancer,
esophageal cancer and hepatocellular carcinoma. It is useful for diagnosis and monitoring of pancreatic cancer

Carbohydrate
antigen 19-9 (CA19-9) is the sialylated form of Lewis Antigen. It may be
elevated in many types of gastrointestinal cancer, such as colorectal cancer,
esophageal cancer and hepatocellular carcinoma. It is useful for diagnosis and monitoring of pancreatic cancer

CA242, known as carbohydrate antigen 242, is a sialyated carbohydrate antigen. It is a cancer-associated glycoprotein expressed in the sera of pancreatic cancer patients. CA242 is a useful biomarker for the diagnosis, prognosis, and surveillance of gastrointestinal malignancies.

CA242, known as carbohydrate antigen 242, is a sialyated carbohydrate antigen. It is a cancer-associated glycoprotein expressed in the sera of pancreatic cancer patients. CA242 is a useful biomarker for the diagnosis, prognosis, and surveillance of gastrointestinal malignancies.

CA242, known as carbohydrate antigen 242, is a sialyated carbohydrate antigen. It is a cancer-associated glycoprotein expressed in the sera of pancreatic cancer patients. CA242 is a useful biomarker for the diagnosis, prognosis, and surveillance of gastrointestinal malignancies.

CA242, known as carbohydrate antigen 242, is a sialyated carbohydrate antigen. It is a cancer-associated glycoprotein expressed in the sera of pancreatic cancer patients. CA242 is a useful biomarker for the diagnosis, prognosis, and surveillance of gastrointestinal malignancies.

CA242, known as carbohydrate antigen 242, is a sialyated carbohydrate antigen. It is a cancer-associated glycoprotein expressed in the sera of pancreatic cancer patients. CA242 is a useful biomarker for the diagnosis, prognosis, and surveillance of gastrointestinal malignancies.